FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes

被引：3
|
作者：
Montesinos, Pau [1 ]
de la Rubia, Javier [1 ]
Orti, Guillermo [1 ]
Sanz, Jaime [1 ]
Martinez, David [1 ]
Mendoza, Ninotchka [2 ]
Scaff, Miguel [1 ]
Paciello, Mariliz [1 ]
Romero, Monica [1 ]
Martin, Guillermo [1 ]
Lorenzo, Ignacio [1 ]
Martinez, Jesus [1 ]
Algarra, Lorenzo [1 ]
Jarque, Isidro [1 ]
Perez-Sirvent, Mariluz [1 ]
Sanz, Guillermo [1 ]
Sanz, Miguel A. [1 ]
机构：
[1] Hosp Univ La Fe, Valencia, Spain
[2] CSS Arnulfo Arias Madrid, Panama City, Panama
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2866.2866
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2866
引用
收藏
页码：843A / 843A
页数：1
相关论文
共 50 条
  • [21] Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia
    Liat Shargian-Alon
    Ofir Wolach
    Uri Rozovski
    Dafna Yahav
    Michal Sela-Navon
    Mazal Rubinstein
    Nino Oniashvilli
    Oren Pasvolsky
    Pia Raanani
    Moshe Yeshurun
    Annals of Hematology, 2020, 99 : 2939 - 2945
  • [22] Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia
    Shargian-Alon, Liat
    Wolach, Ofir
    Rozovski, Uri
    Yahav, Dafna
    Sela-Navon, Michal
    Rubinstein, Mazal
    Oniashvilli, Nino
    Pasvolsky, Oren
    Raanani, Pia
    Yeshurun, Moshe
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2939 - 2945
  • [23] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
    F. Ferrara
    L. Melillo
    M. Montillo
    F. Leoni
    A. Pinto
    G. Mele
    S. Mirto
    Annals of Hematology, 1999, 78 : 380 - 384
  • [24] EFFICACY OF THE FLAG-IDA REGIMEN AS FIRST LINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM A SINGLE CENTER
    Bernardi, M.
    Tassara, M.
    Crotta, A.
    Messina, C.
    Peccatori, J.
    Assanelli, A.
    Clerici, D.
    Mastaglio, S.
    Ciceri, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 279 - 279
  • [25] High remission rate with the FLAG-IDA regimen in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) patients up to 70 years old.
    Bernardi, M
    Ciceri, F
    Camba, L
    Peccatori, J
    Lunghi, F
    Milani, R
    Corradini, P
    Bregni, M
    BLOOD, 2002, 100 (11) : 337B - 337B
  • [26] Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Martin, Mike G.
    Augustin, Kristan M.
    Uy, Geoffrey L.
    Welch, John S.
    Hladnik, Lindsay
    Goyal, Sagun
    Tiwari, Divya
    Monahan, Ryan S.
    Reichley, Richard M.
    Cashen, Amanda F.
    Stockerl-Goldstein, Keith
    Westervelt, Peter
    Abboud, Camille N.
    DiPersio, John F.
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (11) : 733 - 737
  • [27] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Wei, Guoqing
    Ni, Wanmao
    Chiao, Jen-wei
    Cai, Zhen
    Huang, He
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [28] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Guoqing Wei
    Wanmao Ni
    Jen-wei Chiao
    Zhen Cai
    He Huang
    Delong Liu
    Journal of Hematology & Oncology, 4
  • [29] Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia
    Borthakur, Gautam
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Patel, Keyur
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Daver, Naval G.
    Yilmaz, Musa
    Estrov, Zeev E.
    Ohanian, Maro N.
    Maduike, Rita
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [30] Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).
    Wickramanayake, PD
    Steinmetz, HT
    Katay, I
    Glasmacher, A
    Staib, P
    Diehl, V
    BLOOD, 1995, 86 (10) : 3009 - 3009
12345